Balanced news tone
News Sentiment
2096 sentiment intelligence
Simcere Pharmaceutical Group Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+5.4% over one week, +22.2% over four weeks, trend inactive, and materially above fair value.
[HKEX Correction] Simcere Pharmaceutical (02096.HK) received an increase of 100,000 ordinary shares held by Peng Suqin, valued at approximately HK$1.048 million.
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
[HKEX Correction] Simcere Pharmaceutical (02096.HK) received an increase of 100,000 ordinary shares held by Peng Suqin, valued at approximately HK$1.048 million.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 10:33
- Source
- 富途牛牛
Hong Kong Stock Market Alert | Simcere Pharmaceutical (02096) Surges Over 6% Intraday Following Global Drug Discovery and Development Collaboration Agreement with U.S.-based Schrödinger, Inc.
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jul 2026 10:20
- Source
- 富途牛牛
ETFs Investing in Simcere Pharmaceutical Group Limited Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 16:54
- Source
- TradingView
Simcere Pharmaceutical Group (SEHK:2096) Stock Could Be 70% Below Fair Value After Stanford IPF Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 21 Jun 2026 07:00
- Source
- simplywall.st
BRIEF: Simcere Pharma profit surges in 2025
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 26 Feb 2026 08:00
- Source
- thebambooworks.com
Boehringer Ingelheim in deal with China's Simcere Pharma to license IBD drug candidate
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 27 Jan 2026 08:00
- Source
- Reuters
China’s Simcere Pharmaceutical Advances At Home After Exit From NYSE
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Sep 2021 07:00
- Source
- Forbes
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Mar 2021 07:00
- Source
- PR Newswire
SIMCERE PHARMACEUTICAL GROUP LTD. (2096)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Oct 2020 07:00
- Source
- hkex.com.hk